Axogen (AXGN) Net Equity Issued and Repurchased (2013 - 2026)

Axogen (AXGN) posted Net Equity Issued and Repurchased of $134.0 million for Q1 2026, up 13404300.0% on a QoQ basis from $1000.0 in Q4 2018.

Analysis

Axogen (AXGN) Net Equity Issued and Repurchased (2013 - 2026) Analysis & Trends

Axogen has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $134.0 million in Q1 2026.

On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $134.0 million in Q1 2026; TTM through Jun 2026 was $134.0 million, a 13404300.0% increase from a year earlier, with the FY2020 full-year figure at $3.5 million, changed N/A from the prior year.
Net Equity Issued and Repurchased was $134.0 million for Q1 2026 at Axogen, up from $1000.0 in the prior quarter.
The five-year high for Net Equity Issued and Repurchased was $134.0 million in Q1 2026, with the low at $134.0 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Abbott Laboratories	187.42 Bn	182.47 Bn	7.27 Bn	-
2	Intuitive Surgical	129.78 Bn	124.69 Bn	1.96 Bn	-
3	Medtronic	120.53 Bn	112.33 Bn	6.34 Bn	20.00 Mn
4	Stryker	116.28 Bn	112.80 Bn	4.50 Bn	-
5	Boston Scientific	69.29 Bn	68.99 Bn	3.85 Bn	-
6	Edwards Lifesciences	51.83 Bn	47.68 Bn	1.35 Bn	-
7	Alcon	34.36 Bn	32.91 Bn	1.68 Bn	-
8	Dexcom	33.17 Bn	31.23 Bn	830.00 Mn	-
9	Steris	21.90 Bn	21.43 Bn	684.20 Mn	-
10	Axogen	2.59 Bn	2.48 Bn	50.67 Mn	-

Historic Data

Download Data